Brief: Kinnate Biopharma Inc. Provides Corporate Update And Highlights Key Upcoming 2022 Milestones
06/01/2022 22:31
Jan 6 (Reuters) - Kinnate Biopharma Inc KNTE.O :
* KINNATE BIOPHARMA INC. PROVIDES CORPORATE UPDATE AND
HIGHLIGHTS
KEY UPCOMING 2022 MILESTONES
* KINNATE BIOPHARMA INC - PLANNED INITIATION OF PHASE 1
TRIAL OF
KIN-3248 FOR FIRST HALF OF 2022 SUBJECT TO IND CLEARANCE BY FDA
* KINNATE BIOPHARMA INC - CASH, CASH EQUIVALENTS AND
INVESTMENTS
EXPECTED TO FUND CURRENT OPERATIONS INTO SECOND HALF OF 2023
* KINNATE BIOPHARMA INC - INITIAL MONOTHERAPY DATA FROM
ONGOING
KN-8701 PHASE 1 TRIAL EXPECTED IN Q3 OF 2022
Source text for Eikon: ID:nGNX9rzf14
Further company coverage: KNTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kinnate Biopharma
See all newsKinnate Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: XOMA Announces Calculation Of Additional Price Per Share And Extension Of Expiration Date For Tender Offer For Kinnate Biopharma Inc
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview